| Name | N-[2-(2-{2-[2-(4-{6-[(6-Acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl}-1-piperazinyl)ethoxy]ethoxy}ethoxy)ethyl]-2-{[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}acetamide |
|---|---|
| Synonyms |
N-[2-(2-{2-[2-(4-{6-[(6-Acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl}-1-piperazinyl)ethoxy]ethoxy}ethoxy)ethyl]-2-{[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}acetamide
MFCD31813815 |
| Description | BSJ-03-123 is a potent, CDK6-selective small-molecule degrader (PROTAC) that uniquely enables rapid pharmacological interrogation of CDK6-dependent functions. |
|---|---|
| In Vitro | BSJ-03-123 is a potent, CDK6-selective small-molecule degrader (PROTAC). Pharmacologic CDK6 degradation targets a selective dependency of acute myeloid leukemia cells, and transcriptomics and phosphoproteomics profiling of acute degradation of CDK6 enabled dynamic mapping of its immediate role in coordinating signaling and transcription. |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C48H57N9O11 |
| Molecular Weight | 937.008 |
| Exact Mass | 936.413025 |
| LogP | 0.28 |
| Index of Refraction | 1.628 |